## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -11.6% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-22.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biotechnologies Corp (ADPT)**
- Source: GuruFocus | 20251207T001016 | Neutral | Relevance: 99%
-  Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 37,212 shares of the company on December 4, 2025. This transaction increases his total holdings to 1,232,312 shares. The stock is considered significantly overvalued based on its GuruFocus Value, with a price-to-GF-Value ratio of 2.1.

**2. Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share Sale - Has The Bull Case Changed?**
- Source: Simply Wall Street | 20251206T052227 | Neutral | Relevance: 99%
-  Adaptive Biotechnologies (ADPT) recently reported Q3 2025 results, beating expectations with US$94 million in revenue and 42.6% year-on-year growth, despite ongoing unprofitability. Concurrently, CFO Kyle Piskel sold 162,820 shares worth approximately US$3.17 million. This article examines how the earnings beat and insider sale, alongside raised 2025 MRD revenue guidance, impact the company's investment narrative, focusing on its growth trajectory versus execution risks and continued losses.

**3. Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares**
- Source: StocksToTrade | 20251207T212227 | Neutral | Relevance: 99%
- Adaptive Biotechnologies (ADPT) CEO Chad M. Robins sold over $3 million in company shares in recent weeks, including 160,734 shares in early December and 89,265 shares in mid-November. This insider selling coincides with a -15.52% stock decline and financial metrics showing operational inefficiencies despite strong revenue growth and liquidity. Analysts maintain a cautiously bearish outlook due to negative profit margins, high P/S ratio, and underperforming capital utilization.

**4. Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting**
- Source: Quiver Quantitative | 20251206T134000 | Bullish | Relevance: 98%
- Adaptive Biotechnologies Corporation announced the expanded interventional use of its clonoSEQ® test at the 67th American Society of Hematology Annual Meeting. The test's ability to guide clinical decisions, particularly in pediatric B-cell acute lymphoblastic leukemia and multiple myeloma, was highlighted across 90 abstracts. clonoSEQ® is an FDA-cleared and Medicare-covered test for detecting measurable residual disease (MRD) in various blood cancers, helping clinicians refine treatment strategies and improve patient outcomes.

**5. Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025**
- Source: Stock Titan | 20251207T052227 | Bullish | Relevance: 98%
-  Adaptive Biotechnologies announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, highlighting 90 abstracts featuring clonoSEQ data, with 17 showing MRD-guided clinical interventions. The phase II EndRAD study notably reported outstanding event-free and overall survival in NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning. This news underscores clonoSEQ's leadership in blood cancer MRD monitoring and its role as a decision-making tool in treatment.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $16 | $11 | +45% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($1.13M) |
| Sells | 11 ($5.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-22.3% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $5.2M in recent transactions.
4. Elevated short interest (8.7%): bears positioning against stock.
5. Near-term weakness: 8.1% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Analyst sentiment positive (1 raises, avg +45%). Insider selling cluster ($5.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 10.7% to -11.6% (-22.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 15.6pp (needs >4.0% for momentum thesis). AM_20 at -9.8% indicates price below own 20MA trend. Underperforming sector by 8.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.28x) but short-term weakness (below SMA20). RSI neutral at 41. Elevated volume (1.7x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -11.63% (CS: 1) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 0.902x | Below |
| vs SMA50 | 0.919x | Below |
| vs SMA200 | 1.282x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.95
- **Stop Loss:** $12.47 (16.6% risk)
- **Target:** $17.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 201
- **Position Value:** $3,004.95
- **Portfolio %:** 3.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*